NO995817D0 - Kinolin- og kinoksalin-forbindelser som inhiberer blodplateavledet vekstfaktor og/eller P561ck-tyrosinkinase - Google Patents

Kinolin- og kinoksalin-forbindelser som inhiberer blodplateavledet vekstfaktor og/eller P561ck-tyrosinkinase

Info

Publication number: NO995817D0
Authority: NO; Norway
Prior art keywords: quinoline; growth factor; tyrosine kinase; derived growth; inhibit platelet
Prior art date: 1997-05-28

Application number

NO995817A

Other languages

English (en)

Other versions

NO995817L (no

NO316377B1 (no

Inventor

Alfred P Spada

Wei He

Michael R Myers

Original Assignee

Rhone Poulenc Rorer Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-05-28

Filing date

1999-11-26

Publication date

1999-11-26

1999-11-26 Application filed by Rhone Poulenc Rorer Pharma filed Critical Rhone Poulenc Rorer Pharma

1999-11-26 Publication of NO995817L publication Critical patent/NO995817L/no

1999-11-26 Publication of NO995817D0 publication Critical patent/NO995817D0/no

2004-01-19 Publication of NO316377B1 publication Critical patent/NO316377B1/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/50—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to ring nitrogen atoms
- C07D241/52—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/50—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to ring nitrogen atoms
- C07D241/54—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/06—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing isoquinuclidine ring systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Oncology (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Transplantation (AREA)
Dermatology (AREA)
Hematology (AREA)
Orthopedic Medicine & Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Quinoline Compounds (AREA)

NO19995817A 1997-05-28 1999-11-26 Kinolin- og kinoksalinforbindelser som inhiberer blodplateavledet vekstfaktor og/eller P56<O>lck</O>-tyrosinkinase, farmas degree ytisk blandinginneholdende detsamme samt anvendelse derav NO316377B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US86445597A	1997-05-28	1997-05-28
US97261497A	1997-11-18	1997-11-18
PCT/US1998/011000 WO1998054157A1 (en)	1997-05-28	1998-05-28	QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR p561ck TYROSINE KINASES

Publications (3)

Publication Number	Publication Date
NO995817L NO995817L (no)	1999-11-26
NO995817D0 true NO995817D0 (no)	1999-11-26
NO316377B1 NO316377B1 (no)	2004-01-19

Family

ID=27127839

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
NO19995817A NO316377B1 (no)	1997-05-28	1999-11-26	Kinolin- og kinoksalinforbindelser som inhiberer blodplateavledet vekstfaktor og/eller P56<O>lck</O>-tyrosinkinase, farmas degree ytisk blandinginneholdende detsamme samt anvendelse derav
NO19995819A NO323721B1 (no)	1997-05-28	1999-11-26	Kinolin- og kinoksalinforbindelser som inhiberer blodplateavledet vekstfaktor og/eller P56lck-tyrosinkinase og farmasoytisk formulering inneholdende det samme, samt anvendelse derav
NO19995818A NO323720B1 (no)	1997-05-28	1999-11-26	Kinolin- og kinoksalinforbindelser som inhiberer blodplateavledet vekstfaktor og/eller P561ck-tyrosinkinase

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
NO19995819A NO323721B1 (no)	1997-05-28	1999-11-26	Kinolin- og kinoksalinforbindelser som inhiberer blodplateavledet vekstfaktor og/eller P56lck-tyrosinkinase og farmasoytisk formulering inneholdende det samme, samt anvendelse derav
NO19995818A NO323720B1 (no)	1997-05-28	1999-11-26	Kinolin- og kinoksalinforbindelser som inhiberer blodplateavledet vekstfaktor og/eller P561ck-tyrosinkinase

Country Status (25)

Country	Link
EP (3)	EP1001945B1 (no)
JP (3)	JP2002500675A (no)
KR (2)	KR100440756B1 (no)
CN (3)	CN1140516C (no)
AP (3)	AP1554A (no)
AT (3)	ATE493389T1 (no)
AU (3)	AU751188C (no)
BG (3)	BG64444B1 (no)
BR (3)	BR9809501A (no)
CA (3)	CA2291774A1 (no)
CZ (3)	CZ298521B6 (no)
DE (3)	DE69842077D1 (no)
DK (1)	DK0991628T3 (no)
EA (4)	EA008136B1 (no)
ES (1)	ES2235331T3 (no)
HU (2)	HUP0004807A3 (no)
IL (3)	IL133008A0 (no)
NO (3)	NO316377B1 (no)
OA (3)	OA11264A (no)
PL (3)	PL195552B1 (no)
PT (1)	PT991628E (no)
SI (1)	SI0991628T1 (no)
SK (4)	SK158099A3 (no)
UA (1)	UA57790C2 (no)
WO (3)	WO1998054156A1 (no)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BR9809501A (pt) *	1997-05-28	2000-06-20	Rhone Poulenc Rorer Pharma	Composto, composição farmacêutica, e, processos para inibir a atividade da tirosina quinase pdgf, para inibir a atividade da tirosina quinase lck, para inibir a proliferação celular, diferenciação ou liberação de mediador em um paciente, para tratar uma patologia ligada a um distúrbio hiperproliferativo, para tratar a restenose, e, para tratar inflamação em um paciente
US6245760B1 (en) *	1997-05-28	2001-06-12	Aventis Pharmaceuticals Products, Inc	Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
US6159978A (en)	1997-05-28	2000-12-12	Aventis Pharmaceuticals Product, Inc.	Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
US6180632B1 (en) *	1997-05-28	2001-01-30	Aventis Pharmaceuticals Products Inc.	Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
GB9904103D0 (en)	1999-02-24	1999-04-14	Zeneca Ltd	Quinoline derivatives
US6506769B2 (en)	1999-10-06	2003-01-14	Boehringer Ingelheim Pharmaceuticals, Inc.	Heterocyclic compounds useful as inhibitors of tyrosine kinases
US7101869B2 (en)	1999-11-30	2006-09-05	Pfizer Inc.	2,4-diaminopyrimidine compounds useful as immunosuppressants
JP5000068B2 (ja)	2000-08-11	2012-08-15	ベーリンガーインゲルハイムファーマシューティカルズインコーポレイテッド	チロシンキナーゼのインヒビターとして有用な複素環化合物
SI1497266T1 (sl)	2002-03-27	2008-10-31	Glaxo Group Ltd	Derivati kinolina in njihova uporaba kot ligandi 5-ht6
DE10237423A1 (de) *	2002-08-16	2004-02-19	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen
US20050043233A1 (en) *	2003-04-29	2005-02-24	Boehringer Ingelheim International Gmbh	Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
AU2004261582C1 (en)	2003-07-22	2010-01-07	Arena Pharmaceuticals, Inc.	Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
UA85698C2 (ru)	2004-01-16	2009-02-25	Уайет	Хинолиновые промежуточные соединения для синтеза ингибиторов рецепторной тирозинкиназы и способ их получения
EP2150255A4 (en)	2007-05-10	2011-10-05	Glaxosmithkline Llc	CHINOXALINE DERIVATIVES AS P13 KINASE INHIBITORS
US9084742B2 (en)	2007-12-12	2015-07-21	Axovant Sciences Ltd.	Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-Quinoline
US20110021538A1 (en)	2008-04-02	2011-01-27	Arena Pharmaceuticals, Inc.	Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US9126946B2 (en)	2008-10-28	2015-09-08	Arena Pharmaceuticals, Inc.	Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
EP2241557A1 (de)	2009-04-02	2010-10-20	Æterna Zentaris GmbH	Chinoxalin-Derivate und deren Anwendung zur Behandlung gutartiger und bösartiger Tumorerkrankungen
CN102596932A (zh)	2009-09-04	2012-07-18	拜耳医药股份有限公司	作为酪氨酸苏氨酸激酶抑制剂的取代氨基喹喔啉
GB201007286D0 (en)	2010-04-30	2010-06-16	Astex Therapeutics Ltd	New compounds
CN101823998B (zh) *	2010-05-05	2015-03-25	江苏利田科技股份有限公司	一种反应器耦合模拟移动床乙氧基喹啉清洁生产工艺
PL2624695T3 (pl)	2010-10-08	2016-03-31	Nivalis Therapeutics Inc	Nowe podstawione związki chinolinowe jako inhibitory reduktazy S-nitrozoglutationu
GB201020179D0 (en)	2010-11-29	2011-01-12	Astex Therapeutics Ltd	New compounds
US8785643B2 (en)	2010-12-16	2014-07-22	N30 Pharmaceuticals, Inc.	Substituted bicyclic aromatic compounds as S-nitrosoglutathione reductase inhibitors
US8754114B2 (en)	2010-12-22	2014-06-17	Incyte Corporation	Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
GB201118675D0 (en)	2011-10-28	2011-12-14	Astex Therapeutics Ltd	New compounds
GB201118652D0 (en)	2011-10-28	2011-12-07	Astex Therapeutics Ltd	New compounds
GB201118656D0 (en)	2011-10-28	2011-12-07	Astex Therapeutics Ltd	New compounds
GB201118654D0 (en)	2011-10-28	2011-12-07	Astex Therapeutics Ltd	New compounds
ES2605946T3 (es)	2012-03-14	2017-03-17	Bayer Intellectual Property Gmbh	Imidazopiridazinas sustituidas
US9296701B2 (en)	2012-04-24	2016-03-29	Vertex Pharmaceuticals Incorporated	DNA-PK inhibitors
GB201209609D0 (en)	2012-05-30	2012-07-11	Astex Therapeutics Ltd	New compounds
GB201209613D0 (en)	2012-05-30	2012-07-11	Astex Therapeutics Ltd	New compounds
CN107652289B (zh)	2012-06-13	2020-07-21	因塞特控股公司	作为fgfr抑制剂的取代的三环化合物
US9388185B2 (en)	2012-08-10	2016-07-12	Incyte Holdings Corporation	Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en)	2012-12-19	2016-02-23	Incyte Holdings Corporation	Fused pyrazoles as FGFR inhibitors
CA2904641C (en)	2013-03-12	2021-07-20	Vertex Pharmaceuticals Incorporated	Dna-pk inhibitors
JP6449244B2 (ja)	2013-04-19	2019-01-09	インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅＨｏｌｄｉｎｇｓＣｏｒｐｏｒａｔｉｏｎ	Ｆｇｆｒ抑制剤としての二環式複素環
GB201307577D0 (en)	2013-04-26	2013-06-12	Astex Therapeutics Ltd	New compounds
JP2016526534A (ja)	2013-06-11	2016-09-05	バイエル・ファルマ・アクティエンゲゼルシャフト	置換トリアゾロピリジンのプロドラッグ誘導体
WO2015058067A1 (en)	2013-10-17	2015-04-23	Vertex Pharmaceuticals Incorporated	Co-crystals of (s)-n-methyl-8-(1-((2'-methyl-[4,5'-bipyrimidin]-6-yl)amino)propan-2-yl)quinoline-4-carboxamide and deuterated derivatives thereof as dna-pk inhibitors
JO3512B1 (ar)	2014-03-26	2020-07-05	Astex Therapeutics Ltd	مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
CA2943687C (en)	2014-03-26	2024-02-13	Astex Therapeutics Ltd	Combinations of an fgfr inhibitor and an igf1r inhibitor
RU2715236C2 (ru)	2014-03-26	2020-02-26	Астекс Терапьютикс Лтд	Комбинации
US10851105B2 (en)	2014-10-22	2020-12-01	Incyte Corporation	Bicyclic heterocycles as FGFR4 inhibitors
JOP20200201A1 (ar)	2015-02-10	2017-06-16	Astex Therapeutics Ltd	تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
ES2751669T3 (es)	2015-02-20	2020-04-01	Incyte Corp	Heterociclos bicíclicos como inhibidores FGFR
WO2016134294A1 (en)	2015-02-20	2016-08-25	Incyte Corporation	Bicyclic heterocycles as fgfr4 inhibitors
MA41551A (fr)	2015-02-20	2017-12-26	Incyte Corp	Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US10478494B2 (en)	2015-04-03	2019-11-19	Astex Therapeutics Ltd	FGFR/PD-1 combination therapy for the treatment of cancer
KR20180022792A (ko)	2015-06-12	2018-03-06	엑소반트 사이언시즈 게엠베하	렘 수면 행동 장애의 예방 및 치료에 유용한 디아릴 및 아릴헤테로아릴 우레아 유도체
US10034859B2 (en)	2015-07-15	2018-07-31	Axovant Sciences Gmbh	Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
US10399946B2 (en)	2015-09-10	2019-09-03	Laurel Therapeutics Ltd.	Solid forms of an S-Nitrosoglutathione reductase inhibitor
ES2811845T3 (es)	2015-09-23	2021-03-15	Janssen Pharmaceutica Nv	Heterociclos tricíclicos para el tratamiento del cáncer
US11542247B2 (en)	2015-09-23	2023-01-03	Janssen Pharmaceutica Nv	Bi-heteroaryl substitute 1,4-benzodiazepines and uses thereof for the treatment of cancer
EP3518931A4 (en)	2016-09-27	2020-05-13	Vertex Pharmaceuticals Incorporated	METHOD FOR TREATING CANCER WITH A COMBINATION OF DNA-DAMAGING SUBSTANCES AND DNA-PK INHIBITORS
AR111960A1 (es)	2017-05-26	2019-09-04	Incyte Corp	Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
PE20210919A1 (es)	2018-05-04	2021-05-19	Incyte Corp	Sales de un inhibidor de fgfr
CN119241541A (zh)	2018-05-04	2025-01-03	因赛特公司	Fgfr抑制剂的固体形式和其制备方法
WO2020185532A1 (en)	2019-03-08	2020-09-17	Incyte Corporation	Methods of treating cancer with an fgfr inhibitor
US11591329B2 (en)	2019-07-09	2023-02-28	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
WO2021067374A1 (en)	2019-10-01	2021-04-08	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
GEP20247679B (en)	2019-10-14	2024-10-10	Incyte Corp	Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en)	2019-10-16	2023-01-31	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
CA3163875A1 (en)	2019-12-04	2021-06-10	Incyte Corporation	Tricyclic heterocycles as fgfr inhibitors
IL293001A (en)	2019-12-04	2022-07-01	Incyte Corp	Derivatives of fgfr repressors
US12012409B2 (en)	2020-01-15	2024-06-18	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
JP2024513575A (ja)	2021-04-12	2024-03-26	インサイト・コーポレイション	Ｆｇｆｒ阻害剤及びネクチン－４標的化剤を含む併用療法
AR126101A1 (es)	2021-06-09	2023-09-13	Incyte Corp	Heterociclos tricíclicos como inhibidores de fgfr
WO2022261160A1 (en)	2021-06-09	2022-12-15	Incyte Corporation	Tricyclic heterocycles as fgfr inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3483704D1 (de) *	1983-07-22	1991-01-17	Du Pont	Phenylchinolinsaeure und derivate als antitumormittel.
US4888427A (en) *	1987-04-07	1989-12-19	University Of Florida	Amino acids containing dihydropyridine ring systems for site-specific delivery of peptides to the brain
GB9004483D0 (en) *	1990-02-28	1990-04-25	Erba Carlo Spa	New aryl-and heteroarylethenylene derivatives and process for their preparation
US5710158A (en)	1991-05-10	1998-01-20	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5480883A (en) *	1991-05-10	1996-01-02	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
EP0584222B1 (en) *	1991-05-10	1997-10-08	Rhone-Poulenc Rorer International (Holdings) Inc.	Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
US6177401B1 (en) *	1992-11-13	2001-01-23	Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften	Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
KR100224135B1 (ko) *	1993-01-28	1999-10-15	다께다 구니오	퀴놀린 또는 퀴나졸린 유도체, 그 제조 및 용도
DE4426373A1 (de) *	1994-07-26	1996-02-01	Bayer Ag	3-Substituierte Chinolin-5-carbonsäurederivate und Verfahren zu ihrer Herstellung
CN1077107C (zh) *	1996-07-19	2002-01-02	武田药品工业株式会社	杂环化合物、其制备和用途
AU5574798A (en) *	1997-01-21	1998-08-07	Nissan Chemical Industries Ltd.	Industrial antimicrobial/mildew-proofing agents, algicides and antifouling agents containing n-quinoxalylanilines
BR9809501A (pt) *	1997-05-28	2000-06-20	Rhone Poulenc Rorer Pharma	Composto, composição farmacêutica, e, processos para inibir a atividade da tirosina quinase pdgf, para inibir a atividade da tirosina quinase lck, para inibir a proliferação celular, diferenciação ou liberação de mediador em um paciente, para tratar uma patologia ligada a um distúrbio hiperproliferativo, para tratar a restenose, e, para tratar inflamação em um paciente

1998
- 1998-05-28 BR BR9809501-3A patent/BR9809501A/pt not_active Application Discontinuation
- 1998-05-28 UA UA99127137A patent/UA57790C2/uk unknown
- 1998-05-28 PL PL98337087A patent/PL195552B1/pl not_active IP Right Cessation
- 1998-05-28 EA EA199901092A patent/EA008136B1/ru not_active IP Right Cessation
- 1998-05-28 CN CNB98806538XA patent/CN1140516C/zh not_active Expired - Fee Related
- 1998-05-28 EA EA199901086A patent/EA002600B1/ru not_active IP Right Cessation
- 1998-05-28 SI SI9830741T patent/SI0991628T1/ unknown
- 1998-05-28 PL PL98337084A patent/PL194670B1/pl not_active IP Right Cessation
- 1998-05-28 AU AU77079/98A patent/AU751188C/en not_active Ceased
- 1998-05-28 WO PCT/US1998/010999 patent/WO1998054156A1/en not_active Ceased
- 1998-05-28 JP JP50096599A patent/JP2002500675A/ja not_active Ceased
- 1998-05-28 AT AT98926129T patent/ATE493389T1/de not_active IP Right Cessation
- 1998-05-28 CA CA002291774A patent/CA2291774A1/en not_active Abandoned
- 1998-05-28 DE DE69842077T patent/DE69842077D1/de not_active Expired - Lifetime
- 1998-05-28 WO PCT/US1998/011036 patent/WO1998054158A1/en not_active Ceased
- 1998-05-28 JP JP50096499A patent/JP2002513417A/ja not_active Ceased
- 1998-05-28 CN CN98806430A patent/CN1261353A/zh active Pending
- 1998-05-28 AP APAP/P/1999/001710A patent/AP1554A/en active
- 1998-05-28 IL IL13300898A patent/IL133008A0/xx not_active IP Right Cessation
- 1998-05-28 CZ CZ0415899A patent/CZ298521B6/cs not_active IP Right Cessation
- 1998-05-28 AT AT98925022T patent/ATE286886T1/de not_active IP Right Cessation
- 1998-05-28 DE DE69842151T patent/DE69842151D1/de not_active Expired - Lifetime
- 1998-05-28 HU HU0004807A patent/HUP0004807A3/hu unknown
- 1998-05-28 AU AU77062/98A patent/AU747026B2/en not_active Ceased
- 1998-05-28 SK SK1580-99A patent/SK158099A3/sk unknown
- 1998-05-28 AU AU78037/98A patent/AU742739B2/en not_active Ceased
- 1998-05-28 PL PL337086A patent/PL194980B1/pl unknown
- 1998-05-28 DK DK98925022T patent/DK0991628T3/da active
- 1998-05-28 JP JP50098799A patent/JP2002500676A/ja not_active Ceased
- 1998-05-28 AT AT98925041T patent/ATE500233T1/de not_active IP Right Cessation
- 1998-05-28 AP APAP/P/1999/001711A patent/AP1362A/en active
- 1998-05-28 EP EP98925041A patent/EP1001945B1/en not_active Expired - Lifetime
- 1998-05-28 BR BR9809515-3A patent/BR9809515A/pt not_active Application Discontinuation
- 1998-05-28 EP EP98926129A patent/EP1001946B1/en not_active Expired - Lifetime
- 1998-05-28 SK SK114-2005A patent/SK286084B6/sk not_active IP Right Cessation
- 1998-05-28 CN CN98806454A patent/CN1280572A/zh active Pending
- 1998-05-28 AP APAP/P/1999/001709A patent/AP1444A/en active
- 1998-05-28 HU HU0002084A patent/HUP0002084A3/hu unknown
- 1998-05-28 SK SK1579-99A patent/SK157999A3/sk unknown
- 1998-05-28 EP EP98925022A patent/EP0991628B1/en not_active Expired - Lifetime
- 1998-05-28 CZ CZ0417999A patent/CZ298490B6/cs not_active IP Right Cessation
- 1998-05-28 BR BR9809172-7A patent/BR9809172A/pt not_active Application Discontinuation
- 1998-05-28 KR KR10-1999-7011036A patent/KR100440756B1/ko not_active Expired - Fee Related
- 1998-05-28 WO PCT/US1998/011000 patent/WO1998054157A1/en not_active Ceased
- 1998-05-28 EA EA199901090A patent/EA004103B1/ru not_active IP Right Cessation
- 1998-05-28 CZ CZ0418099A patent/CZ296845B6/cs not_active IP Right Cessation
- 1998-05-28 KR KR10-1999-7010972A patent/KR100425638B1/ko not_active Expired - Fee Related
- 1998-05-28 ES ES98925022T patent/ES2235331T3/es not_active Expired - Lifetime
- 1998-05-28 IL IL13300998A patent/IL133009A0/xx not_active IP Right Cessation
- 1998-05-28 DE DE69828607T patent/DE69828607T2/de not_active Expired - Lifetime
- 1998-05-28 CA CA002291728A patent/CA2291728A1/en not_active Abandoned
- 1998-05-28 PT PT98925022T patent/PT991628E/pt unknown
- 1998-05-28 CA CA002291750A patent/CA2291750A1/en not_active Abandoned
- 1998-05-28 SK SK1581-99A patent/SK158199A3/sk unknown
- 1998-05-28 IL IL13300798A patent/IL133007A/xx not_active IP Right Cessation
1999
- 1999-11-23 EA EA200100575A patent/EA007807B1/ru not_active IP Right Cessation
- 1999-11-26 NO NO19995817A patent/NO316377B1/no unknown
- 1999-11-26 NO NO19995819A patent/NO323721B1/no unknown
- 1999-11-26 NO NO19995818A patent/NO323720B1/no unknown
- 1999-11-29 OA OA9900260A patent/OA11264A/en unknown
- 1999-11-29 OA OA9900262A patent/OA11222A/en unknown
- 1999-11-29 OA OA9900261A patent/OA11221A/en unknown
- 1999-12-08 BG BG103963A patent/BG64444B1/bg unknown
- 1999-12-08 BG BG103965A patent/BG64419B1/bg unknown
- 1999-12-14 BG BG104006A patent/BG64445B1/bg unknown

Also Published As

Publication number	Publication date
NO995817L (no)	1999-11-26
BG103963A (en)	2000-07-31
EA199901090A1 (ru)	2000-08-28
WO1998054157A1 (en)	1998-12-03
AU7803798A (en)	1998-12-30
AP9901710A0 (en)	1999-12-31
DK0991628T3 (da)	2005-05-17
OA11222A (en)	2003-07-16
AU751188C (en)	2005-06-30
EA007807B1 (ru)	2007-02-27
NO995818D0 (no)	1999-11-26
AP1362A (en)	2005-01-19
EA004103B1 (ru)	2003-12-25
IL133007A (en)	2005-06-19
AP9901711A0 (en)	1999-12-31
ATE493389T1 (de)	2011-01-15
CA2291774A1 (en)	1998-12-03
CA2291728A1 (en)	1998-12-03
NO995819D0 (no)	1999-11-26
EP1001945A1 (en)	2000-05-24
NO316377B1 (no)	2004-01-19
PL337084A1 (en)	2000-07-31
BG104006A (en)	2000-07-31
NO323721B1 (no)	2007-06-25
EP1001945B1 (en)	2011-03-02
DE69828607T2 (de)	2006-01-05
BG64444B1 (en)	2005-02-28
SK158199A3 (en)	2000-06-12
SI0991628T1 (en)	2005-06-30
NO323720B1 (no)	2007-06-25
WO1998054156A1 (en)	1998-12-03
CZ298490B6 (cs)	2007-10-17
IL133009A0 (en)	2001-03-19
AP9901709A0 (en)	1999-12-31
EA200100575A1 (ru)	2002-02-28
HUP0002084A2 (hu)	2000-10-28
PL195552B1 (pl)	2007-10-31
KR100440756B1 (ko)	2004-07-21
BG64445B1 (en)	2005-02-28
ATE500233T1 (de)	2011-03-15
AP1444A (en)	2005-07-18
BR9809515A (pt)	2000-06-20
EP1001946B1 (en)	2010-12-29
PL337087A1 (en)	2000-07-31
DE69842077D1 (de)	2011-02-10
KR20010013057A (ko)	2001-02-26
SK286084B6 (sk)	2008-03-05
SK157999A3 (en)	2000-06-12
AU7707998A (en)	1998-12-30
UA57790C2 (uk)	2003-07-15
AU742739B2 (en)	2002-01-10
HUP0002084A3 (en)	2000-12-28
JP2002500676A (ja)	2002-01-08
JP2002513417A (ja)	2002-05-08
EA002600B1 (ru)	2002-06-27
CN1261354A (zh)	2000-07-26
IL133007A0 (en)	2001-03-19
EA008136B1 (ru)	2007-04-27
HK1028042A1 (en)	2001-02-02
IL133008A0 (en)	2001-03-19
BG103965A (en)	2000-07-31
EP1001946A1 (en)	2000-05-24
AU751188B2 (en)	2002-08-08
PL337086A1 (en)	2000-07-31
NO995818L (no)	1999-11-26
EA199901086A1 (ru)	2000-06-26
OA11221A (en)	2003-07-16
EA199901092A1 (ru)	2000-06-26
HUP0004807A3 (en)	2001-12-28
PL194670B1 (pl)	2007-06-29
DE69828607D1 (de)	2005-02-17
CA2291750A1 (en)	1998-12-03
PT991628E (pt)	2005-05-31
AU7706298A (en)	1998-12-30
ATE286886T1 (de)	2005-01-15
CN1280572A (zh)	2001-01-17
CZ418099A3 (cs)	2000-05-17
SK158099A3 (en)	2000-06-12
OA11264A (en)	2002-11-19
WO1998054158A1 (en)	1998-12-03
HUP0004807A2 (hu)	2001-11-28
BG64419B1 (bg)	2005-01-31
AU747026B2 (en)	2002-05-09
BR9809172A (pt)	2000-08-01
EP0991628A1 (en)	2000-04-12
ES2235331T3 (es)	2005-07-01
KR20010039512A (ko)	2001-05-15
CZ415899A3 (cs)	2000-05-17
NO995819L (no)	1999-11-26
CZ417999A3 (cs)	2000-05-17
EP1001945A4 (en)	2000-07-26
PL194980B1 (pl)	2007-07-31
CN1140516C (zh)	2004-03-03
CZ298521B6 (cs)	2007-10-24
JP2002500675A (ja)	2002-01-08
DE69842151D1 (de)	2011-04-14
BR9809501A (pt)	2000-06-20
KR100425638B1 (ko)	2004-04-03
EP1001946A4 (en)	2000-07-26
CN1261353A (zh)	2000-07-26
AP1554A (en)	2006-01-18
EP0991628B1 (en)	2005-01-12
EP0991628A4 (en)	2000-07-26
CZ296845B6 (cs)	2006-07-12

Publication	Publication Date	Title
NO995818D0 (no)	1999-11-26	Kinolin- og kinoksalin-forbindelser som inhiberer blodplateavledet vekstfaktor og/eller P561ck-tyrosinkinase
NZ512096A (en)	2004-01-30	Quinoline and quinoxaline compounds as PDGF-receptor and/or LCK tyrosine kinase inhibitors
BG105629A (en)	2002-02-28	Quinoline and quinoxaline compounds
DE60015594D1 (de)	2004-12-09	Imidazolderivate und deren verwendung als raf kinase inhibitoren
ATE230394T1 (de)	2003-01-15	Indolderivate und deren verwendung zur behandlung von malignen und anderen, auf pathologischen zellproliferationen beruhenden erkrankungen
ATE302005T1 (de)	2005-09-15	N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren
ATE302606T1 (de)	2005-09-15	N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren
ECSP045139A (es)	2004-07-23	DERIVADOS DE ACETILENO QUE TIENEN ACTIVIDAD ANTAGONISTICA DE MGluR5
EA200100576A1 (ru)	2002-02-28	Хинолиновые и хиноксалиновые соединения, как ингибиторы тфр-р и/или lck тирозинкиназы
BRPI0409173A (pt)	2006-04-11	compostos e composições como inibidores de proteìna quinase
TR200200883T2 (tr)	2002-09-23	2-ikameli 1,1-bifenil-2-karbonamidler, imalat yöntemleri, ilaç olarak kullanılmaları
BG105112A (bg)	2001-10-31	Средство с антидепресивно действие
SE9804212D0 (sv)	1998-12-04	Compounds
DE60112574D1 (de)	2005-09-15	Bicyclische cyclohexylamine und ihre verwendung als nmda-rezeptor antagonisten
GB9907048D0 (en)	1999-05-19	Novel glucocorticoid receptor ligands for the treatment of meta bolic disorders